Table 2.
List of FDA-approved epidrugs.
| Generic name | Brand name (company) | Indication (s) | Mechanism of action | Year approved |
|---|---|---|---|---|
| Vorinostat | Zolinza (Merck & Co.) | Cutaneous T cell lymphoma | HDAC inhibitor | 2006 |
| Decitabine | Dacogen (MGI Pharma) | Myelodysplastic Diseases | DNMT inhibitor | 2006 |
| Azacitidine | Vidaza (Pharmion) | Myelodysplastic Diseases | DNMT inhibitor | 2009 |
| Onureg (BMS) | Acute Myeloid Leukemia | 2020 | ||
| Romidepsin | Istodax (Gloucester) | Cutaneous T cell lymphoma | HDAC inhibitor | 2009 |
| Istodax (BMS) | Peripheral T cell lymphomas (withdrawn 2021) | 2011 | ||
| Valproic Acid | Depacon, Depakene, etc (Abbott, others) | Epilepsy, Bipolar mania, Migraine prophylaxis | HDAC inhibitor | 2010 |
| Belinostat | Beleodaq (Spectrum) | Peripheral T cell lymphomas | HDAC inhibitor | 2014 |
| Panobinostat | Farydak (Secura Bio) | Multiple Myeloma (discontinued 2021) | HDAC inhibitor | 2015 |
| Tazemetostat | Tazverik (Epizyme) | Epithelioid Sarcoma; Follicular Lymphoma | EZH2 inhibitor | 2020 |